STORM Therapeutics Secures $56 Million Series C Financing and Doses First Patient in Phase 2 Sarcoma Trial of STC‑15

Storm Therapeutics raises $56M to advance cancer drugs

Cambridge biotech STORM Therapeutics raises $56M

STC-15 is the world’s first RNA-modifying enzyme inhibitor to reach human trials. Phase 1 showed durable tumour regression across multiple sarcoma subtypes. The $56M Series C is backed entirely by existing investors including Pfizer Ventures and M Ventures. STORM Therapeutics, a Cambridge-based clinical-stage biotech targeting RNA modifications to treat cancer, has raised $56 million in […] This story continues at The Next Web

STORM Therapeutics Secures $56 Million Series C Financing and Doses First Patient in Phase 2 Sarcoma Trial of STC‑15

The proceeds will support the advancement of STC-15 in a Phase 2 study in select sarcoma indicationsFirst‑in‑class METTL3 inhibitor reprograms malignant progenitor cells by...

MeiraGTx buys back gene therapy from J&J; Storm brings in $56M Series C; Adlai Nortye nabs $150M

MeiraGTx buys back gene therapy from J&J; Storm brings in $56M Series C; Adlai Nortye nabs $150M; FDA delays decision for Savara’s lung disease drug; longevity biotech Nula debuts with up to $30M; Aligos secures hepB treatment license in Asia

Storm clinches $56m in Series C for Phase II on lead sarcoma drug

The Pfizer-backed Series C round will see Storm work out an accelerated approval pathway for STC-15 in sarcoma.The post Storm clinches $56m in Series C for Phase II on lead sarcoma drug appeared first on Clinical Trials Arena.